• Report data error
  • Print

Notice FR17C1058

Report data error

Close

NALTREXONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE NALTREXONE ET,BUPROPION OU SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE BUPROPION

Publication No. and date FR17C1058 - 2018-01-12 (BOPI 2018-02)
Kind CCP de médicament
Application No. and date of filing FR17C1058 - 2017-12-08
First authorization in France FR - EU/1/14/988 - 2015-03-30
First authorization in the EC CE - EU/1/14/988 - 2015-03-30
Product description (For SPC) NALTREXONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE NALTREXONE ET,BUPROPION OU SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE BUPROPION
Publication No. and date of the basic patent EP2316456 - 2011-05-04
Application No. and date of filing of the basic patent EP10185782 - 2004-04-21
French title of the basic patent COMPOSITIONS COMPRENANT UN ANTAGONISTE DES OPIOIDES ET BUPROPION POUR INFLUENCER LA PERTE DE POIDS

Parties

Applicant(s) :

OREXIGEN THERAPEUTICS, INC. - 3344 NORTH TORREY PINES COURT, SUITE 200 - LA JOLLA, CA 92037 - US

Proprietor(s) :

OREXIGEN THERAPEUTICS, INC. - 3344 NORTH TORREY PINES COURT, SUITE 200 - LA JOLLA, CA 92037 - US

Representative :

ERNEST GUTMANN YVES PLASSERAUD SAS - 3 RUE AUBER - 75009 PARIS - FR - Number Siren : 332417500

Status in France

Next renewal fee 2024-04-30

Last update of the patents database: 2018-02-16